NZ592943A - Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases - Google Patents
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseasesInfo
- Publication number
- NZ592943A NZ592943A NZ592943A NZ59294309A NZ592943A NZ 592943 A NZ592943 A NZ 592943A NZ 592943 A NZ592943 A NZ 592943A NZ 59294309 A NZ59294309 A NZ 59294309A NZ 592943 A NZ592943 A NZ 592943A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- inflammatory response
- modulation
- autoimmune diseases
- chronic inflammatory
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150081923 IL4 gene Proteins 0.000 title 1
- 230000012085 chronic inflammatory response Effects 0.000 title 1
- 102000004388 Interleukin-4 Human genes 0.000 abstract 3
- 108090000978 Interleukin-4 Proteins 0.000 abstract 3
- 229940028885 interleukin-4 Drugs 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 abstract 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801601 | 2008-11-17 | ||
| PCT/DK2009/050304 WO2010054667A1 (en) | 2008-11-17 | 2009-11-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592943A true NZ592943A (en) | 2012-09-28 |
Family
ID=41510516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592943A NZ592943A (en) | 2008-11-17 | 2009-11-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8546321B2 (enExample) |
| EP (1) | EP2365983B1 (enExample) |
| JP (1) | JP5750373B2 (enExample) |
| CN (1) | CN102216323B (enExample) |
| AU (1) | AU2009316076B2 (enExample) |
| BR (1) | BRPI0921717A2 (enExample) |
| CA (1) | CA2743394C (enExample) |
| ES (1) | ES2620437T3 (enExample) |
| IL (1) | IL212962A0 (enExample) |
| NZ (1) | NZ592943A (enExample) |
| RU (1) | RU2542375C2 (enExample) |
| WO (1) | WO2010054667A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2665486B1 (en) | 2011-01-18 | 2019-12-25 | Bioniz, LLC | Compositions for modulating gamma-c-cytokine activity |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| CA2980087A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| US12600757B2 (en) | 2017-04-07 | 2026-04-14 | Bioniz Therapeutics, Inc. | Peptides inhibiting gamma-c-cytokine activity and methods of use |
| KR102095284B1 (ko) * | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
| EP3530320B1 (en) | 2018-02-27 | 2023-11-15 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| CA3137971A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| CN118401250A (zh) | 2022-01-05 | 2024-07-26 | 塞罗德斯有限公司 | 用于治疗肥胖症的il-4衍生肽 |
| AU2023262616B2 (en) * | 2022-04-29 | 2024-07-11 | Serodus Aps | Il-4 derived peptide fragments for use in the treatment of diabetic nephropathy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05503088A (ja) * | 1989-11-21 | 1993-05-27 | ザ ユニバーシティー オブ メルボルン | 抗炎症用の組成物及び方法 |
| ATE136906T1 (de) * | 1989-12-20 | 1996-05-15 | Schering Corp | Antikörperantagonisten gegen humanes interleukin- 4 |
| US6337072B1 (en) * | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| EP1156823B1 (en) * | 1999-02-12 | 2008-10-29 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US20030056244A1 (en) * | 2000-05-02 | 2003-03-20 | Ning Huang | Feed additive compositions and methods |
| FR2838444B1 (fr) * | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| JP2007537989A (ja) * | 2003-10-16 | 2007-12-27 | アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定化ペプチド |
-
2009
- 2009-11-17 NZ NZ592943A patent/NZ592943A/xx not_active IP Right Cessation
- 2009-11-17 EP EP09764175.7A patent/EP2365983B1/en active Active
- 2009-11-17 CN CN200980145907.4A patent/CN102216323B/zh not_active Expired - Fee Related
- 2009-11-17 US US13/127,574 patent/US8546321B2/en active Active
- 2009-11-17 ES ES09764175.7T patent/ES2620437T3/es active Active
- 2009-11-17 JP JP2011535880A patent/JP5750373B2/ja active Active
- 2009-11-17 RU RU2011121971/10A patent/RU2542375C2/ru not_active IP Right Cessation
- 2009-11-17 AU AU2009316076A patent/AU2009316076B2/en not_active Ceased
- 2009-11-17 BR BRPI0921717A patent/BRPI0921717A2/pt not_active IP Right Cessation
- 2009-11-17 WO PCT/DK2009/050304 patent/WO2010054667A1/en not_active Ceased
- 2009-11-17 CA CA2743394A patent/CA2743394C/en active Active
-
2011
- 2011-05-17 IL IL212962A patent/IL212962A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009316076B2 (en) | 2015-11-19 |
| BRPI0921717A2 (pt) | 2018-10-09 |
| US20110300148A1 (en) | 2011-12-08 |
| WO2010054667A1 (en) | 2010-05-20 |
| CN102216323A (zh) | 2011-10-12 |
| IL212962A0 (en) | 2011-07-31 |
| RU2011121971A (ru) | 2012-12-27 |
| EP2365983A1 (en) | 2011-09-21 |
| US8546321B2 (en) | 2013-10-01 |
| RU2542375C2 (ru) | 2015-02-20 |
| CN102216323B (zh) | 2016-08-03 |
| EP2365983B1 (en) | 2016-12-28 |
| JP5750373B2 (ja) | 2015-07-22 |
| JP2012508698A (ja) | 2012-04-12 |
| ES2620437T3 (es) | 2017-06-28 |
| AU2009316076A1 (en) | 2010-05-20 |
| CA2743394C (en) | 2018-01-02 |
| CA2743394A1 (en) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592943A (en) | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| WO2009014650A3 (en) | Recombinant vibrio cholerae exotoxins | |
| MX2013010342A (es) | Uso de dosis bajas de il-2 para tratar transtornos inflamatorios o relacionados con la autoinmunidad. | |
| IL193846A (en) | Use of a n-terminal peptide that has been re-regulated to produce a drug to treat inflammatory conditions | |
| MX2014005411A (es) | Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
| PH12012500632B1 (en) | Pharmaceutical compositions comprising bi-1356 and metformin | |
| WO2008124849A3 (en) | Pyrrolo-pyridine kinase modulators | |
| WO2009038671A3 (en) | Oxylipin compounds for treating autoimmune diseases | |
| IL216084A0 (en) | 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation | |
| EP2104507A4 (en) | T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR CANCER THERAPY | |
| EP3103476A3 (en) | Antibodies against a proliferating inducing ligand (april) | |
| IL202170A0 (en) | Parthenocarpic genetic elements derived from s. habrochaites | |
| EP2121739A4 (en) | NOVEL POLYPEPTIDE HAVING ANTITUMOR ACTIVITY | |
| MX2012013735A (es) | Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos. | |
| SG154441A1 (en) | Treatment of demyelinating disorders | |
| GB0613362D0 (en) | Therapeutic delivery of carbon monoxide | |
| IL218321A0 (en) | Therapeutic agent for mood disorders | |
| PH12012500897A1 (en) | Novel arylated camphenes, processes for their preparation and uses thereof | |
| WO2010119102A3 (de) | Pharmaceutische zusammensetzung enthaltend protonenpumpenhemmer zur behandlung von dermatologischen autoimmunerkrankungen | |
| WO2008037497A3 (en) | Galectin-2 for the treatment of inflammatory diseases of the skin | |
| GB2458429B (en) | Novel mesenchymal progenitor cells derived from human blastocyst-derived stem cells | |
| EP2165735A4 (en) | BIOPHYSIOLOGICAL REGULATOR FOR THERAPEUTIC TREATMENTS | |
| GB0819096D0 (en) | Pressure metal gauze assembly | |
| WO2010041827A3 (en) | NF-κB INHIBITOR CONTAINING ARH1 PROTEIN OR GENE ENCODING THE SAME | |
| MX2010011055A (es) | Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 NOV 2016 BY FB RICE Effective date: 20131106 |
|
| LAPS | Patent lapsed |